358 related articles for article (PubMed ID: 28817997)
1. Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis.
Afolabi D; Albor C; Zalewski L; Altmann DR; Baker D; Schmierer K
Mult Scler; 2018 Oct; 24(11):1461-1468. PubMed ID: 28817997
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies.
Giovannoni G; Comi G; Rammohan K; Rieckmann P; Dangond F; Keller B; Jack D; Vermersch P
Adv Ther; 2021 Sep; 38(9):4975-4985. PubMed ID: 34370275
[TBL] [Abstract][Full Text] [Related]
3. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
Giovannoni G; Cook S; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Hamlett A; Viglietta V; Greenberg S;
Lancet Neurol; 2011 Apr; 10(4):329-37. PubMed ID: 21397565
[TBL] [Abstract][Full Text] [Related]
4. Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies.
Kita M; Fox RJ; Gold R; Giovannoni G; Phillips JT; Sarda SP; Kong J; Viglietta V; Sheikh SI; Okwuokenye M; Kappos L
Clin Ther; 2014 Dec; 36(12):1958-1971. PubMed ID: 25315404
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
Hettle R; Harty G; Wong SL
J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
[TBL] [Abstract][Full Text] [Related]
6. Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study.
Ali S; Paracha N; Cook S; Giovannoni G; Comi G; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Greenberg S; Scott DA; Joyeux A;
Clin Drug Investig; 2012 Jan; 32(1):15-27. PubMed ID: 22017519
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.
Giovannoni G; Soelberg Sorensen P; Cook S; Rammohan K; Rieckmann P; Comi G; Dangond F; Adeniji AK; Vermersch P
Mult Scler; 2018 Oct; 24(12):1594-1604. PubMed ID: 28870107
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal.
Pinheiro B; Guerreiro R; Costa J; Miguel LS
J Med Econ; 2020 May; 23(5):484-491. PubMed ID: 31951777
[No Abstract] [Full Text] [Related]
9. Assessing the Long-Term Effectiveness of Cladribine vs. Placebo in the Relapsing-Remitting Multiple Sclerosis CLARITY Randomized Controlled Trial and CLARITY Extension Using Treatment Switching Adjustment Methods.
Bell Gorrod H; Latimer NR; Damian D; Hettle R; Harty GT; Wong SL
Adv Ther; 2020 Jan; 37(1):225-239. PubMed ID: 31701485
[TBL] [Abstract][Full Text] [Related]
10. CLICK-MS and MASTER-2 Phase IV trial design: cladribine tablets in suboptimally controlled relapsing multiple sclerosis.
Miravalle AA; Katz J; Robertson D; Hayward B; Harlow DE; Lebson LA; Sloane JA; Bass AD; Fox EJ
Neurodegener Dis Manag; 2021 Apr; 11(2):99-111. PubMed ID: 33517769
[TBL] [Abstract][Full Text] [Related]
11. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
Giovannoni G; Comi G; Cook S; Rammohan K; Rieckmann P; Soelberg Sørensen P; Vermersch P; Chang P; Hamlett A; Musch B; Greenberg SJ;
N Engl J Med; 2010 Feb; 362(5):416-26. PubMed ID: 20089960
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study.
Giovannoni G; Soelberg Sorensen P; Cook S; Rammohan KW; Rieckmann P; Comi G; Dangond F; Hicking C; Vermersch P
Mult Scler; 2019 May; 25(6):819-827. PubMed ID: 29716436
[TBL] [Abstract][Full Text] [Related]
13. Disease stability over five years in people with multiple sclerosis treated with cladribine tablets: a plain language summary.
Giovannoni G; Comi G; Rammohan K; Rieckmann P; Dangond F; Jack D; Vermersch P
Neurodegener Dis Manag; 2022 Dec; 12(6):295-301. PubMed ID: 36017780
[TBL] [Abstract][Full Text] [Related]
14. Application of Item Response Theory to Modeling of Expanded Disability Status Scale in Multiple Sclerosis.
Novakovic AM; Krekels EH; Munafo A; Ueckert S; Karlsson MO
AAPS J; 2017 Jan; 19(1):172-179. PubMed ID: 27634384
[TBL] [Abstract][Full Text] [Related]
15. Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5 years: a plain language summary.
Stefano N; Sormani MP; Giovannoni G; Rammohan K; Leist TP; Coyle PK; Dangond F; Alexandri N; Galazka A
Neurodegener Dis Manag; 2022 Dec; 12(6):303-310. PubMed ID: 36017797
[TBL] [Abstract][Full Text] [Related]
16. Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies.
De Stefano N; Sormani MP; Giovannoni G; Rammohan K; Leist T; Coyle PK; Dangond F; Keller B; Alexandri N; Galazka A
Mult Scler; 2022 Jan; 28(1):111-120. PubMed ID: 33969750
[TBL] [Abstract][Full Text] [Related]
17. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis.
Cook S; Leist T; Comi G; Montalban X; Giovannoni G; Nolting A; Hicking C; Galazka A; Sylvester E
Mult Scler Relat Disord; 2019 Apr; 29():157-167. PubMed ID: 30885374
[TBL] [Abstract][Full Text] [Related]
18. Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis.
Sipe JC
Expert Rev Neurother; 2010 Mar; 10(3):365-75. PubMed ID: 20187859
[TBL] [Abstract][Full Text] [Related]
19. Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study.
Brochet B; Solari A; Lechner-Scott J; Piehl F; Langdon D; Hupperts R; Selmaj K; Patti F; Brieva L; Maida EM; Alexandri N; Smyk A; Nolting A; Keller B; Montalban X; Kubala Havrdova E
Mult Scler; 2023 Dec; 29(14):1808-1818. PubMed ID: 37978852
[TBL] [Abstract][Full Text] [Related]
20. Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis.
Comi G; Hartung HP; Kurukulasuriya NC; Greenberg SJ; Scaramozza M
Expert Opin Pharmacother; 2013 Jan; 14(1):123-36. PubMed ID: 23256518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
